Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina, 1998, The New England Journal of Medicine, 338, 1498, 10.1056/NEJM199805213382103 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee, 1996, Lancet, 348, 1329, 10.1016/S0140-6736(96)09457-3 Abbott, 2004, PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues, Bioorganic & Medicinal Chemistry Letters, 14, 2847, 10.1016/j.bmcl.2004.03.043 Achuthan, 2015, Hydroxychloroquine's efficacy as an antiplatelet agent study in healthy volunteers: A proof of concept study, Journal of Cardiovascular Pharmacology and Therapeutics, 20, 174, 10.1177/1074248414546324 Akand, 2015, Effect of sildenafil on platelet function and platelet cGMP of patients with erectile dysfunction, Andrologia, 47, 1098, 10.1111/and.12387 Akers, 2010, Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: A direct, parenteral P2Y12 receptor antagonist, Journal of Clinical Pharmacology, 50, 27, 10.1177/0091270009344986 Andre, 2002, CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism, Nature Medicine, 8, 247, 10.1038/nm0302-247 Andrews, 2007, The 14-3-3zeta-GPIb-IX-V complex as an antiplatelet target, Drug News & Perspectives, 20, 285, 10.1358/dnp.2007.20.5.1120215 Anfossi, 1996, Interplay between milrinone and adenosine in the inhibition of human platelet response, General Pharmacology, 27, 1149, 10.1016/S0306-3623(96)00050-X Angiolillo, 2012, Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial, Jama, 307, 265, 10.1001/jama.2011.2002 Arthur, 2017, Platelet hyperreactivity in diabetes: Focus on GPVI signaling-are useful drugs already available?, Diabetes, 66, 7, 10.2337/db16-1098 Arzamendi, 2011, An anti-von willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis, Clinical and Applied Thrombosis/Hemostasis, 17, E70, 10.1177/1076029610384114 Asai, 2006, Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans, Platelets, 17, 209, 10.1080/09537100600565551 Ataga, 2017, Crizanlizumab for the prevention of pain crises in sickle cell disease, The New England Journal of Medicine, 376, 429, 10.1056/NEJMoa1611770 Aziret, 2014, The effects of vardenafil and pentoxifylline administration in an animal model of ischemic colitis, Clinics (São Paulo, Brazil), 69, 763, 10.6061/clinics/2014(11)10 Bach, 2013, Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. Separation of the antithrombotic effect and bleeding for candidate drug AZD1283, Journal of Medicinal Chemistry, 56, 7015, 10.1021/jm400820m Bae, 2012, Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an anti-vWF aptamer, against thrombotic risk, Archives of Pharmacal Research, 35, 1693, 10.1007/s12272-012-1000-3 Becattini, 2012, New oral anticoagulants for venous thromboembolism: Focus on factor Xa and thrombin inhibitors, Current Drug Discovery Technologies, 9, 119, 10.2174/1570163811209020119 Belleville-Rolland, 2016, MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease, Pharmacological Research, 107, 381, 10.1016/j.phrs.2016.04.002 Benimana, 2017, The progress in the research of antiplatelet agents (1995-2017), Future Medicinal Chemistry, 9, 1087, 10.4155/fmc-2017-0001 Berger, 2009, American Heart Journal, 158, 998, 10.1016/j.ahj.2009.10.010 Bhagwat, 1985, Synthesis and structure of the platelet aggregation factor thromboxane A2, Nature, 315, 511, 10.1038/315511a0 Bhatt, 2009, Intravenous platelet blockade with cangrelor during PCI, The New England Journal of Medicine, 361, 2330, 10.1056/NEJMoa0908629 Bhatt, 2013, Effect of platelet inhibition with cangrelor during PCI on ischemic events, The New England Journal of Medicine, 368, 1303, 10.1056/NEJMoa1300815 Bird, 2011, Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-beta inhibitor in mice, Thrombosis Research, 127, 560, 10.1016/j.thromres.2011.02.007 Blue, 2009, Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist, Blood, 114, 195, 10.1182/blood-2008-08-169243 Boldron, 2014, N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methyl piperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist, Journal of Medicinal Chemistry, 57, 7293, 10.1021/jm500588w Bonaca, 2015, Long-term use of ticagrelor in patients with prior myocardial infarction, The New England Journal of Medicine, 372, 1791, 10.1056/NEJMoa1500857 Bonaca, 2014, Coronary stent thrombosis with vorapaxar versus placebo: Results from the TRA 2 degrees P-TIMI 50 trial, Journal of the American College of Cardiology, 64, 2309, 10.1016/j.jacc.2014.09.037 Bonaca, 2013, Vorapaxar in patients with peripheral artery disease: Results from TRA2{degrees}P-TIMI 50, Circulation, 127, 1522, 10.1161/CIRCULATIONAHA.112.000679 Bousser, 2011, Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial, Lancet, 377, 2013, 10.1016/S0140-6736(11)60600-4 Breddin, 1980, The German-Austrian aspirin trial: A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction on behalf of the German-Austrian study group, Circulation, 62, V63 Breddin, 1980, Secondary prevention of myocardial infarction: A comparison of acetylsalicylic acid, placebo and phenprocoumon, Haemostasis, 9, 325 Buerke, 1997, Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro, Thrombosis Research, 88, 89, 10.1016/S0049-3848(97)00221-1 Cannon, 2007, Journal of the American College of Cardiology, 50, 1844, 10.1016/j.jacc.2007.07.053 Cattaneo, 2015, P2Y12 receptors: Structure and function, Journal of Thrombosis and Haemostasis, 13, S10, 10.1111/jth.12952 Chen, 2002, The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion, The Journal of Biological Chemistry, 277, 3011, 10.1074/jbc.M109714200 Chen, 2016, Potent and orally bioavailable antiplatelet agent, PLD-301, with the potential of overcoming clopidogrel resistance, Letters in Drug Design & Discovery, 13, 250, 10.2174/1570180812666150730221941 Chen, 2016, NF-kappaB signaling pathway as target for antiplatelet activity, Blood, 30, 309, 10.1016/j.blre.2016.03.002 Chen, 2012, Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis, Japanese Journal of Clinical Oncology, 42, 761, 10.1093/jjco/hys087 Chen, 2013, Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: A meta-analysis, Journal of Clinical Pharmacology, 53, 532, 10.1002/jcph.64 Cheng, 1999, Cilostazol, Heart Disease, 1, 182 Chopra, 2011, Successful use of prasugrel, an alternative antiplatelet agent, in a patient with clopidogrel allergy, Annals of Allergy, Asthma & Immunology, 107, 541, 10.1016/j.anai.2011.08.003 Choudhury, 1996, Plasma serotonin and platelet aggregation during ischemia-reperfusion in dogs: Effect of dipyridamole and coenzyme Q10, Haemostasis, 26, 38 Cohen, 2016, Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction, Journal of Thrombosis and Thrombolysis, 41, 464, 10.1007/s11239-015-1227-1 Cunningham, 2016, Proteinase-activated receptors (PARs) as targets for antiplatelet therapy, Biochemical Society Transactions, 44, 606, 10.1042/BST20150282 Cushing, 2012, Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans, Clinical and Experimental Pharmacology & Physiology, 39, 3, 10.1111/j.1440-1681.2011.05616.x Danielak, 2018, Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy, Expert Opinion on Pharmacotherapy, 19, 103, 10.1080/14656566.2017.1421634 Davi, 2012, Thromboxane receptors antagonists and/or synthase inhibitors, Handbook of Experimental Pharmacology, 261, 10.1007/978-3-642-29423-5_11 Dawson, 1998, Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial, Circulation, 98, 678, 10.1161/01.CIR.98.7.678 De Bon, 2010, Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: A pilot study, Angiology, 61, 602, 10.1177/0003319710362977 Di Minno, 2013, Stroke prevention: From available antiplatelet drugs to novel molecular targets, Current Drug Targets, 14, 3, 10.2174/138945013804806488 Diener, 2008, Lancet Neurology, 7, 875, 10.1016/S1474-4422(08)70198-4 Doggrell, 2001, ReoPro rules: Results from the 'Do tirofiban and reopro give similar efficacy Trial' (TARGET), Expert Opinion on Pharmacotherapy, 2, 1507, 10.1517/14656566.2.9.1507 Dogne, 2002, Thromboxane A2 inhibition: Therapeutic potential in bronchial asthma, American Journal of Respiratory Medicine, 1, 11, 10.1007/BF03257158 Dombi, 2017, Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin, European Journal of Haematology, 98, 106, 10.1111/ejh.12806 Dumas, 2012, Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist, British Journal of Pharmacology, 165, 1827, 10.1111/j.1476-5381.2011.01668.x Dutting, 2012, Platelet GPVI: A target for antithrombotic therapy?!, Trends in Pharmacological Sciences, 33, 583, 10.1016/j.tips.2012.07.004 Elwood, 1983, British studies of aspirin and myocardial infarction, The American Journal of Medicine, 74, 50, 10.1016/0002-9343(83)90528-4 Fernandez-Ruiz, 2015, Role of sodium tungstate as a potential antiplatelet agent, Drug Design, Development and Therapy, 9, 2777, 10.2147/DDDT.S77221 Ferroni, 2012, Platelet function in health and disease: From molecular mechanisms, redox considerations to novel therapeutic opportunities, Antioxidants & Redox Signaling, 17, 1447, 10.1089/ars.2011.4324 Fiessinger, 2010, Thromboxane antagonism with terutroban in peripheral arterial disease: The TAIPAD study, Journal of Thrombosis and Haemostasis, 8, 2369, 10.1111/j.1538-7836.2010.04020.x Flierl, 2015, Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators, The Journal of Experimental Medicine, 212, 129, 10.1084/jem.20140391 Fontana, 2011, The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin, Journal of Thrombosis and Haemostasis, 9, 2109, 10.1111/j.1538-7836.2011.04446.x Fox, 2013, Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers, Platelets, 24, 392, 10.3109/09537104.2012.704648 Fuentes, 2014, Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: New antiplatelet agents, Vascular Pharmacology, 62, 162, 10.1016/j.vph.2014.05.008 Fuentes, 2014, Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk, Thrombosis Research, 134, 221, 10.1016/j.thromres.2014.04.027 Fuentes, 2016, NF-kappaB signaling pathway as target for antiplatelet activity, Blood Reviews, 30, 309, 10.1016/j.blre.2016.03.002 Furie, 2004, Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation, Trends in Molecular Medicine, 10, 171, 10.1016/j.molmed.2004.02.008 Gachet, 2006, Regulation of platelet functions by P2 receptors, Annual Review of Pharmacology and Toxicology, 46, 277, 10.1146/annurev.pharmtox.46.120604.141207 Gachet, 2006, The platelet P2 receptors in arterial thrombosis, Blood Cells, Molecules & Diseases, 36, 223, 10.1016/j.bcmd.2005.12.024 Geng, 2012, Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: A meta-analysis of 5,821 patients, Cardiology, 122, 148, 10.1159/000338812 Gent, 1989, The canadian American ticlopidine study (CATS) in thromboembolic stroke, Lancet, 1, 1215, 10.1016/S0140-6736(89)92327-1 Giugliano, 2009, Early versus delayed, provisional eptifibatide in acute coronary syndromes, The New England Journal of Medicine, 360, 2176, 10.1056/NEJMoa0901316 Goel, 2013, Ticagrelor: The first approved reversible oral antiplatelet agent, International Journal of Applied & Basic Medical Research, 3, 19, 10.4103/2229-516X.112234 Goto, 2010, Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease, European Heart Journal, 31, 2601, 10.1093/eurheartj/ehq320 Goto, 2010, Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome, Journal of Atherosclerosis and Thrombosis, 17, 156, 10.5551/jat.3038 Gratsianskii, 2004, Do low risk patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel need abciximab infusion? Results of ISAR-REACT study, Kardiologiia, 44, 80 Gresele, 2011, Anti-platelet therapy: Phosphodiesterase inhibitors, British Journal of Clinical Pharmacology, 72, 634, 10.1111/j.1365-2125.2011.04034.x Gurbel, 2010, Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The respond study, Circulation, 121, 1188, 10.1161/CIRCULATIONAHA.109.919456 Gurbel, 2009, Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study, Circulation, 120, 2577, 10.1161/CIRCULATIONAHA.109.912550 Halkes, 2006, Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial, Lancet, 367, 1665, 10.1016/S0140-6736(06)68734-5 Han, 2014, Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: Subgroup analysis from the effect of Cilostazol in acute lacunar infarction based on pulsatility index of transcranial doppler (ECLIPse) study, Cerebrovascular Diseases, 38, 197, 10.1159/000365840 Harrington, 1995, Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention, The American Journal of Cardiology, 76, 1222, 10.1016/S0002-9149(99)80345-2 Harrington, 2009, Platelet inhibition with cangrelor in patients undergoing PCI, The New England Journal of Medicine, 361, 2318, 10.1056/NEJMoa0908628 Hass, 1989, A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine aspirin stroke study group, The New England Journal of Medicine, 321, 501, 10.1056/NEJM198908243210804 Held, 2014, Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: Results from the TRACER trial, European Heart Journal Acute Cardiovascular Care, 3, 246, 10.1177/2048872614527838 Hirsh, 2008, 133, 110s Hitchcock, 2015, Inflammation drives thrombosis after salmonella infection via CLEC-2 on platelets, The Journal of Clinical Investigation, 125, 4429, 10.1172/JCI79070 Husted, 2006, Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin, European Heart Journal, 27, 1038, 10.1093/eurheartj/ehi754 Iavelov, 2008, Tirofiban or abciximab and sirolimus-eluting or bare metal uncoated stents in primary percutaneous coronary intervention for acute myocardial infarction: Results of multistrategy trial, Kardiologiia, 48, 59 Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction, 1998, The New England Journal of Medicine, 338, 1488, 10.1056/NEJM199805213382102 Ishizuka, 2004, Ramatroban (BAY u 3405): A novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor, Cardiovascular Drug Reviews, 22, 71, 10.1111/j.1527-3466.2004.tb00132.x Ito, 1996, Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021, Cellular Signalling, 8, 575, 10.1016/S0898-6568(96)00112-X Jamasbi, 2015, Differential inhibition of human atherosclerotic plaque-induced platelet activation by dimeric GPVI-fc and anti-GPVI antibodies: Functional and imaging studies, Journal of the American College of Cardiology, 65, 2404, 10.1016/j.jacc.2015.03.573 James, 2009, Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial, American Heart Journal, 157, 599, 10.1016/j.ahj.2009.01.003 Japp, 2013, Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans, Journal of the American Heart Association, 2, 10.1161/JAHA.112.006007 Jeng, 2015, The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial, International Journal of Stroke, 10, 123, 10.1111/ijs.12384 Jeon, 2015, Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers, Clinical Therapeutics, 37, 563, 10.1016/j.clinthera.2015.01.010 Jeon, 2014, Bioorganic & Medicinal Chemistry Letters, 24, 1294, 10.1016/j.bmcl.2014.01.066 Jiang, 2014, New advances in treating thrombotic diseases: GPVI as a platelet drug target, Drug Discovery Today, 19, 1471, 10.1016/j.drudis.2014.06.005 Jiang, 2015, Inhibition of glycoprotein VI clustering by collagen as a mechanism of inhibiting collagen-induced platelet responses: The example of losartan, PLoS ONE, 10 Jin, 2005, The Journal of Pharmacology and Experimental Therapeutics, 312, 214, 10.1124/jpet.104.073718 Johnson, 2007, Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589, Platelets, 18, 346, 10.1080/09537100701268741 Juif, 2019, Clinical pharmacology of the reversible and potent P2Y12 receptor antagonist ACT-246475 after single subcutaneous administration in healthy male subjects, Journal of Clinical Pharmacology, 59, 123, 10.1002/jcph.1296 Juneja, 2013, Ticagrelor: An emerging oral antiplatelet agent, Journal of Pharmacology and Pharmacotherapeutics, 4, 78, 10.4103/0976-500X.107698 Jung, 2012, Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood, The Journal of Biological Chemistry, 287, 30000, 10.1074/jbc.M112.359125 Kariyazono, 2001, Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol, Thrombosis Research, 101, 445, 10.1016/S0049-3848(00)00415-1 Kastrati, 2006, Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial, Jama, 295, 1531, 10.1001/jama.295.13.joc60034 Katoh, 2001, Effects of the antiplatelet agent TA-993 and its metabolite MB3 on the hemorheological properties of rat and human erythrocytes, Thrombosis Research, 104, 105, 10.1016/S0049-3848(01)00351-6 Khadse, 2018, Advances in the development of novel factor xa inhibitors: A patent review, Mini Reviews in Medicinal Chemistry, 18, 1332, 10.2174/1389557518666180424120726 Kondo, 1999, Milrinone, a phosphodiesterase inhibitor, suppresses intimal thickening after photochemically induced endothelial injury in the mouse femoral artery, Atherosclerosis, 142, 133, 10.1016/S0021-9150(98)00203-2 Kosoglou, 2012, Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease, European Journal of Clinical Pharmacology, 68, 1049, 10.1007/s00228-012-1217-6 Kosoglou, 2012, Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects, European Journal of Clinical Pharmacology, 68, 249, 10.1007/s00228-011-1120-6 Kuo, 2010, NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities, Naunyn-Schmiedeberg's Archives of Pharmacology, 381, 495, 10.1007/s00210-010-0505-x Latorre, 2016, Regulation of platelet function by acetylation/deacetylation mechanisms, Current Medicinal Chemistry, 23, 3966, 10.2174/0929867323666160907112038 Lecut, 2003, Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived fab fragments, Journal of Thrombosis and Haemostasis, 1, 2653, 10.1111/j.1538-7836.2003.00495.x Lee, 2011, Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent, Archives of Pharmacal Research, 34, 515, 10.1007/s12272-011-0421-8 Lei, 2014, Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis, Thrombosis and Haemostasis, 111, 279, 10.1160/TH13-06-0490 Leonardi, 2018, Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The champion experience, European Heart Journal Acute Cardiovascular Care, 7, 158, 10.1177/2048872616661692 Leonardi, 2010, American Heart Journal, 160, 65, 10.1016/j.ahj.2010.04.008 Leonardi, 2013, Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA.CER) trial, European Heart Journal, 34, 1723, 10.1093/eurheartj/eht104 Li, 2007, The fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats, Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1199, 10.1161/ATVBAHA.107.140590 Li, 2014, RUC-4: A novel alphaIIbbeta3 antagonist for prehospital therapy of myocardial infarction, Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 2321, 10.1161/ATVBAHA.114.303724 Liao, 1998, Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy quinol inone (CCT-62), European Journal of Pharmacology, 349, 107, 10.1016/S0014-2999(98)00181-2 Lim, 2016, Effect of a 4-week treatment with Cilostazol in patients with chronic tinnitus: A randomized, prospective, placebo-controlled, double-blind, pilot study, Journal International Advance Otolaryngol, 12, 170, 10.5152/iao.2016.2682 Liu, 2004, Cilostazol and dipyridamole synergistically inhibit human platelet aggregation, Journal of Cardiovascular Pharmacology, 44, 266, 10.1097/00005344-200408000-00017 Loprete, 2014, Pharmacodynamics and pharmacokinetics of a novel, low-dose, soft-gel capsule of acetylsalicylic acid in comparison with an oral solution after single-dose administration to healthy volunteers: A phase I, two-way crossover study, Clinical Drug Investigation, 34, 19, 10.1007/s40261-013-0145-2 Luci, 2010, Discovery of ML355, a potent and selective inhibitor of human 12-lipoxygenase Mangin, 2012, A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents, The Journal of Pharmacology and Experimental Therapeutics, 341, 156, 10.1124/jpet.111.189050 Mangin, 2017, Targeting 12-lipoxygenase as a potential novel antiplatelet therapy, Cancers (Basel), 38, 1006 Markus, 2011, The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: A randomized trial, Stroke, 42, 2149, 10.1161/STROKEAHA.111.616649 Matsuda, 2016, Effect of Cilostazol on cerebral vasospasm and outcome in patients with aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled trial, Cerebrovascular Diseases, 42, 97, 10.1159/000445509 Matsumoto, 2007, Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization, Thrombosis Research, 119, 319, 10.1016/j.thromres.2006.01.023 Matsuo, 1997, The mechanism of action of KBT-3022, a new antiplatelet agent, General Pharmacology, 28, 229, 10.1016/S0306-3623(96)00190-5 Mawhin, 2015, The receptor EP3 to PGE2: A rational target to prevent atherothrombosis without inducing bleeding, Prostaglandins & Other Lipid Mediators, 121, 4, 10.1016/j.prostaglandins.2015.10.001 Mehran, 2009, Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial, Lancet, 374, 1149, 10.1016/S0140-6736(09)61484-7 Mehta, 2000, The Clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease, European Heart Journal, 21, 2033, 10.1053/euhj.2000.2474 Mehta, 2001, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study, Lancet, 358, 527, 10.1016/S0140-6736(01)05701-4 Moers, 2004, G13-mediated signaling as a potential target for antiplatelet drugs, Drug News & Perspectives, 17, 493, 10.1358/dnp.2004.17.8.863692 Moliterno, 2011, Catheterization and Cardiovascular Interventions, 77, 1001, 10.1002/ccd.22876 Momo, 1992, Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals, Arzneimittelforschung, 42, 32 Moroi, 2003, A new monoclonal antibody, mAb 204-11, that influences the binding of platelet GPVI to fibrous collagen, Thrombosis and Haemostasis, 89, 996, 10.1055/s-0037-1613401 Morrow, 2009, American Heart Journal, 158, 335, 10.1016/j.ahj.2009.06.027 Mukherjee, 2005, Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: Do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up, European Heart Journal, 26, 2524, 10.1093/eurheartj/ehi459 Muller, 2013, von Willebrand factor inhibition improves endothelial function in patients with stable angina, Journal of Cardiovascular Translational Research, 6, 364, 10.1007/s12265-012-9422-3 Murphy, 2003, The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease, American Journal of Cardiovascular Drugs, 3, 101, 10.2165/00129784-200303020-00004 Myou, 2002, Effect of ozagrel hydrochloride, a thromboxane synthetase inhibitor, on alcoholic beverage-induced bronchoconstriction in asthmatic patients, Prostaglandins, Leukotrienes, and Essential Fatty Acids, 66, 397, 10.1054/plef.2002.0365 Nakamura, 2002, Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma, Cerebrovascular Diseases, 14, 234, 10.1159/000065669 Nakashima, 1992, Pharmacokinetics of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in human subjects, Arzneimittelforschung, 42, 60 Naran, 1997, The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects, Thrombosis Research, 88, 399, 10.1016/S0049-3848(97)00271-5 Neri Serneri, 2004, Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study, European Heart Journal, 25, 1845, 10.1016/j.ehj.2004.07.013 Nicholson, 1991, In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent, Thrombosis Research, 62, 567, 10.1016/0049-3848(91)90029-V Nieman, 2016, Protease-activated receptors in hemostasis, Blood, 128, 169, 10.1182/blood-2015-11-636472 Nieswandt, 2003, Platelet-collagen interaction: Is GPVI the central receptor?, Blood, 102, 449, 10.1182/blood-2002-12-3882 Niitsu, 2005, Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity, Seminars in Thrombosis and Hemostasis, 31, 184, 10.1055/s-2005-869524 Nomura, 2004, Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: Therapeutic effects by cilostazol and potentiation by dipyridamole, Platelets, 15, 167, 10.1080/09537100410001682779 Nylander, 2012, Human target validation of phosphoinositide 3-kinase (PI3K)beta: Effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor, Journal of Thrombosis and Haemostasis, 10, 2127, 10.1111/j.1538-7836.2012.04898.x O'Donoghue, 2016, Efficacy and safety of Cangrelor in women versus men during percutaneous coronary intervention: Insights from the cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial, Circulation, 133, 248, 10.1161/CIRCULATIONAHA.115.017300 Ohlmann, 2008, Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI fab fragment in non-human primates without modification of glycoprotein VI expression, Journal of Thrombosis and Haemostasis, 6, 1003, 10.1111/j.1538-7836.2008.02976.x Ohmuro, 1992, Protective effect of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on myocardial damage due to coronary occlusion and reperfusion in rabbit, Arzneimittelforschung, 42, 39 Ono, 2010, Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI, Journal of Medicinal Chemistry, 53, 2087, 10.1021/jm901534d Ottervanger, 2003, Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: One-year survival in the GUSTO IV-ACS (global use of strategies to open occluded coronary arteries IV--acute coronary syndrome) trial, Circulation, 107, 437, 10.1161/01.CIR.0000046487.06811.5E Pan, 2012, BF066, a novel dual target antiplatelet agent without significant bleeding, PLoS ONE, 7 Park, 2014, Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): Study protocol for a randomized controlled trial, Trials, 15, 151, 10.1186/1745-6215-15-151 Peerlinck, 1993, MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man, Circulation, 88, 1512, 10.1161/01.CIR.88.4.1512 Peyvandi, 2016, Caplacizumab for acquired thrombotic thrombocytopenic Purpura, The New England Journal of Medicine, 374, 511, 10.1056/NEJMoa1505533 Pieters, 1993, Antithrombotic activity of bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: A random controlled clinical trial, Thrombosis and Haemostasis, 70, 903, 10.1055/s-0038-1649697 Pingarron-Martin, 2014, Sildenafil effect on prevention of thrombosis after microsurgical anastomosis: Experimental rat model of thrombotic suture, Oral and Maxillofacial Surgery, 18, 53, 10.1007/s10006-012-0387-9 Popma, 1994, Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: The EPIC trial results, Jounal of Invasive Cardiolgy, 6, 45A Priya, 2010, Characterization of 4-methyl-2-oxo-1,2-dihydroquinolin-6-yl acetate as an effective antiplatelet agent, Bioorganic & Medicinal Chemistry, 18, 4085, 10.1016/j.bmc.2010.04.011 Quek, 2000, Fyn and Lyn phosphorylate the fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway, Blood, 96, 4246, 10.1182/blood.V96.13.4246 Regensteiner, 2002, Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: Meta-analysis of six randomized controlled trials, Journal of the American Geriatrics Society, 50, 1939, 10.1046/j.1532-5415.2002.50604.x Rey, 2017, The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat, Pharmacology Research & Perspectives, 5, 10.1002/prp2.338 Robert, 1991, Ticlopidine: A new antiplatelet agent for cerebrovascular disease, Pharmacotherapy, 11, 317 Robinson, 2009, Prasugrel: Newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention, Future Cardiology, 5, 237, 10.2217/fca.09.1 Rollini, 2014, Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: Results of an in vitro pilot investigation, Journal of Thrombosis and Thrombolysis, 37, 131, 10.1007/s11239-013-0979-8 Sakariassen, 2012, EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin, Thrombosis Research, 130, 746, 10.1016/j.thromres.2012.08.309 Schulz, 2010, Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: Implications for thrombus formation, Blood, 115, 4102, 10.1182/blood-2009-07-230268 Serebruany, 2006, Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: The subset from the JUMBO study, Postgraduate Medical Journal, 82, 404, 10.1136/pgmj.2006.047696 Shan, 2012, Overcoming clopidogrel resistance: Discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent, Journal of Medicinal Chemistry, 55, 3342, 10.1021/jm300038c Shattil, 2004, Integrins: Dynamic scaffolds for adhesion and signaling in platelets, Blood, 104, 1606, 10.1182/blood-2004-04-1257 Shinohara, 2010, Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial, Lancet Neurology, 9, 959, 10.1016/S1474-4422(10)70198-8 Siller-Matula, 2014, Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors, Journal of Thrombosis and Haemostasis, 12, 2, 10.1111/jth.12445 Sivenius, 1999, Second European stroke prevention study: Antiplatelet therapy is effective regardless of age. ESPS2 working group, Acta Neurologica Scandinavica, 99, 54, 10.1111/j.1600-0404.1999.tb00658.x Smith, 1991, Prostaglandin and thromboxane biosynthesis, Pharmacology & Therapeutics, 49, 153, 10.1016/0163-7258(91)90054-P Sohn, 2000, Increase of [ca(2+)]i and release of arachidonic acid via activation of M2 receptor coupled to Gi and rho proteins in oesophageal muscle, Cellular Signalling, 12, 215, 10.1016/S0898-6568(99)00085-6 Statkevich, 2012, Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment, European Journal of Clinical Pharmacology, 68, 1501, 10.1007/s00228-012-1269-7 Stone, 2006, Bivalirudin for patients with acute coronary syndromes, The New England Journal of Medicine, 355, 2203, 10.1056/NEJMoa062437 Sun, 2002, New mechanism of action for cilostazol: Interplay between adenosine and cilostazol in inhibiting platelet activation, Journal of Cardiovascular Pharmacology, 40, 577, 10.1097/00005344-200210000-00011 Tai, 2017, Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: A case control study, BMC Neurology, 17, 40, 10.1186/s12883-017-0800-y Takayama, 2008, A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/fc receptor gamma-chain complex, The Journal of Clinical Investigation, 118, 1785, 10.1172/JCI32513 Tam, 1998, Abciximab (ReoPro, chimeric 7E3 fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins, Circulation, 98, 1085, 10.1161/01.CIR.98.11.1085 Tanigawa, 2000, Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention, The American Journal of Cardiology, 85, 1054, 10.1016/S0002-9149(00)00695-0 Tcheng, 1999, Eptifibatide: A potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa, Expert Opinion on Investigational Drugs, 8, 1893, 10.1517/13543784.8.11.1893 Tello-Montoliu, 2012, Pharmacodynamic effects of EV-077: Results of an in vitro pilot investigation in healthy volunteers, Journal of Thrombosis and Thrombolysis, 34, 297, 10.1007/s11239-012-0795-6 Theroux, 2000, Circulation, 102, 2466, 10.1161/01.CIR.102.20.2466 Theroux, 1996, Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina, The Canadian Lamifiban Study Circulation, 94, 899, 10.1161/01.CIR.94.5.899 Thomas, 2015, Platelet P2Y12 inhibitors reduce systemic inflammation and its Prothrombotic effects in an experimental human model, Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 2562, 10.1161/ATVBAHA.115.306528 Tilly, 2014, Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence, Cardiovascular Research, 101, 482, 10.1093/cvr/cvt276 Tobin, 2011, Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: First results from the trinity antiPlatelet responsiveness (TrAP) study, British Journal of Haematology, 152, 640, 10.1111/j.1365-2141.2010.08539.x Toma, 2010, Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease, The Onset/Offset study. Maedica (Buchar), 5, 75 Toque, 2008, Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets, British Journal of Pharmacology, 154, 787, 10.1038/bjp.2008.141 Uchiyama, 2009, Stroke prevention by cilostazol in patients with atherothrombosis: Meta-analysis of placebo-controlled randomized trials, Journal of Stroke and Cerebrovascular Diseases, 18, 482, 10.1016/j.jstrokecerebrovasdis.2009.07.010 Uchiyama, 2014, Benefit of cilostazol in patients with high risk of bleeding: Subanalysis of cilostazol stroke prevention study 2, Cerebrovascular Diseases, 37, 296, 10.1159/000360811 Ueno, 2011, Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel, JACC. Cardiovascular Interventions, 4, 905, 10.1016/j.jcin.2011.05.016 Ueno, 2010, Elinogrel: Pharmacological principles, preclinical and early phase clinical testing, Future Cardiology, 6, 445, 10.2217/fca.10.67 Umemura, 2005, PET study of the neuroprotective effect of TRA-418, an antiplatelet agent, in a monkey model of stroke, Journal of Nuclear Medicine, 46, 1931 Ungerer, 2011, Novel antiplatelet drug revacept (dimeric glycoprotein VI-fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans, Circulation, 123, 1891, 10.1161/CIRCULATIONAHA.110.980623 Valgimigli, 2010, Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: A meta-analysis of randomized trials, European Heart Journal, 31, 35, 10.1093/eurheartj/ehp376 Varga-Szabo, 2008, Cell adhesion mechanisms in platelets, Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 403, 10.1161/ATVBAHA.107.150474 Verro, 2008, Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: A meta-analysis, Stroke, 39, 1358, 10.1161/STROKEAHA.107.496281 Vidal, 2002, Cdc42/Rac1-dependent activation of the p21-activated kinase (PAK) regulates human platelet lamellipodia spreading: Implication of the cortical-actin binding protein cortactin, Blood, 100, 4462, 10.1182/blood.V100.13.4462 Voelker, 2012, Dissolution and pharmacokinetics of a novel micronized aspirin formulation, Inflammopharmacology, 20, 225, 10.1007/s10787-011-0099-z Wallentin, 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, The New England Journal of Medicine, 361, 1045, 10.1056/NEJMoa0904327 Wang, 1984, XC 386: A new antiplatelet agent, Thrombosis Research, 36, 113, 10.1016/0049-3848(84)90333-5 Wang, 2017, Leukocyte integrin mac-1 regulates thrombosis via interaction with platelet GPIbalpha, Nature Communications, 8, 15559, 10.1038/ncomms15559 van de Werf, 1996, More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. latest results from the EPILOG and CAPTURE trials, European Heart Journal, 17, 325, 10.1093/oxfordjournals.eurheartj.a014858 Wilson, 2018, PAR4 (protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo Thrombus formation, Arteriosclerosis, Thrombosis, and Vascular Biology, 38, 448, 10.1161/ATVBAHA.117.310104 Wiviott, 2005, Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial, Circulation, 111, 3366, 10.1161/CIRCULATIONAHA.104.502815 Yang, 2014, Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents, Journal of Medicinal Chemistry, 57, 6150, 10.1021/jm5006226 Yu, 1992, Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets, Biochemical Pharmacology, 43, 323, 10.1016/0006-2952(92)90295-T Zafar, 2010, A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel a randomised phase I study, Thrombosis and Haemostasis, 103, 205, 10.1160/TH09-06-0378 Zhang, 2012, Ozagrel for acute ischemic stroke: A meta-analysis of data from randomized controlled trials, Neurological Research, 34, 346, 10.1179/1743132812Y.0000000022 Zhang, 2001, Antiplatelet mechanism of 2-chloro-3-(4-hexylphenyl)-amino-1,4-naphthoquinone (NQ304), an antithrombotic agent, Pharmacology & Toxicology, 88, 181, 10.1034/j.1600-0773.2001.d01-101.x Zhao, 1999, Circulation, 100, 1609, 10.1161/01.CIR.100.15.1609 Zheng, 2016, Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura, Blood Adv, 1, 75, 10.1182/bloodadvances.2016000711 Zhu, 2017, Vol. 129, 1840